Expression of CD52 in peripheral T-cell lymphoma. by Piccaluga PP et al.
Letters to the Editor
| 566 | haematologica/the hematology journal | 2007; 92(04)
Expression of CD52 in peripheral T-cell lymphoma 
Peripheral T-cell lymphoma unspecified
(PTCL/U) is a rare tumor characterized by poor
treatment response and a dismal prognosis. We
studied CD52 expression in 97 PTCL/U cases by
immunohistochemistry on tissue-microarrays.
Furthermore, CD52 gene expression was studied in
28 cases for which RNA was available. We found
that CD52 is expressed in approximately 40% of
PTCLs/U at the same level as in normal T-lympho-
cytes. Although other factors may play a role in the
in vivo response to alemtuzumab, an anti-CD52
monoclonal antibody, the estimation of CD52
expression may provide a rationale for the selec-
tion of patients with a higher probability of treat-
ment response. 
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Peripheral T-cell lymphomas (PTCLs) are a heteroge-
neous group of tumors that the WHO classification basi-
cally subdivides into specified and unspecified (U).1 In
Western countries, they correspond to 15% of non-
Hodgkin’s lymphomas,1 and more often present in
advanced stage in middle aged/elderly patients who die
rapidly despite aggressive therapies.2 Recently, novel clin-
ical/pathological scores have been proposed to improve
prognostic stratification of PTCL/U patients.3,4 However,
novel targeted therapies are needed.  
CDw52, originally characterized as a human leukocyte
differentiation antigen, is present on the surface of most
peripheral blood lymphocytes, macrophages, and mono-
cytes at relatively high density. It is absent from myeloid
cells, platelets, and erythroid cells as well as hematopoi-
etic stem cells.5 Campath-1H (alemtuzumab) is a human-
ized antibody against CD52 currently approved for
chronic lymphocytic leukemia (CLL) therapy.6
Furthermore, anti-CD52 showed interesting activity in T-
prolymphocytic leukemia (disease characterized by high
CD52 expression) and cutaneous T-cell lymphomas.7
Only some data are available regarding alemtuzumab in
PTCL/U,7,8 which is often characterized by an aberrant
lack of surface antigens.4 Although other factors can affect
the response to alemtuzumab in vivo, it is conceivable
that lack of CD52 expression may play a major role in
determining refractoriness to the compound. The aim of
this study was to examine CD52 expression in PTCL/U
to evaluate the potential for a more rationale use of alem-
tuzumab in this highly aggressive disorder. 
We studied the expression of CD52 on tissue micro-
arrays (TMAs) from 148 PTCL/U cases.4 Ninety-seven
out of 148 cases turned were evaluable due to core loss
following repeated cutting. In addition, frozen material
was available from 28 cases and gene expression profiles
(GEP) were generated and compared to that of 20 sam-
ples of normal T-lymphocytes. These had been collected
from peripheral blood and reactive tonsils of healthy
donors.9 In order to avoid the confusing effect of reactive
components, only cases with 70-90% of neoplastic ele-
ments were chosen for GEP-analysis. GEP were generat-
ed and analyzed as previously reported9 by using the HG-
U133 2.0 plus micro-arrays (Affymetrix, Inc.
http://www.affymetrix.com/support/index.affx). All patients
had given permission for use of samples for research and
study approval was obtained from the Local Ethical
Committee. 
Anti-CD52 (rat anti-human, monoclonal; Serotec ltd,
Oxford, UK) was applied at a 1:200 dilution on a
TechMate 500 immunostainer and revealed by the
EnVision+ technique.4 Before immunohistochemistry, the
sections underwent antigen retrieval in citrate buffer
(pH=6.0) in a micro-waver at 900W (3 cycles lasting 5’
each). The TMAs were scored by two experienced
pathologists, who estimated the number of positive cells.
Cores were considered positive if 30% or more of the
tumor cells were stained.4
We found that overall CD52 was down-regulated in
PTCL/U when compared with normal T-lymphocytes (T-
test, p<0.0000001). In particular, in 17/28 PTCL/U (60%),
CD52 expression level was below the lowest value
recorded in normal T-cells (Figure 1). In addition, it was
detected by immunohistochemistry in 40 out of the 97
(41%) evaluable PTCLs. Notably, GEP paralleled CD52
staining in those cases undergoing both molecular analy-
sis and immunohistochemistry. In particular, the median
gene expression level was 5,031.00 compared with
1,804.00 in cases CD52+ and CD52– at immunohisto-
chemistry respectively (p<0.05). Interestingly, all the
samples of normal T-lymphocytes, representing the sup-
posed normal counterparts of this tumor, were CD52
positive, suggesting that PTCL/U often lacks its expres-
Figure 1. CD52 expression in PTCL/U. A. CD52 expres-
sion in peripheral T-cell lymphoma unspecified
(PTCL/U) evaluated by gene expression analysis and
immunohistochemistry as percentage of positive
cases. B. CD52 gene expression in PTCL/U and normal
T-cells. Raw expression data are reported on y axis. C.
PTCL/U: neoplastic cells are negative at CD52 determi-
nation. Note the internal control represented by scat-
tered reactive T-lymphocytes, which are clearly distinct
from neoplastic elements due to both normal T-cell
antigen expression and lack of cytological atipia.
(Immunoperoxidase Envision+ Technique; Gill’s hema-
toxylin counterstaining; x200). D. PTCL/U: neoplastic
cells infiltrating a normal germinal center (GC) strong-
ly express CD52. Note the negativity of residual ele-
ments of the mantle zone (MZ) (Immunoperoxidase
Envision+ Technique; Gill’s hematoxylin counterstain-
ing; x200). Inset: Neoplastic cells show overt nuclear
shape and size variability and high nuclear/cytoplas-
mic ratio (Immunoperoxidase Envision+ Technique;
Gill’s hematoxylin counterstaining; x600). 
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sion at both the RNA and protein level. This is not sur-
prising as we found CD2, CD3, CD4, CD5, CD7, and
CD8 variably expressed.4 In other words, defectivity of T-
cell associated antigens seems to be a hallmark of neo-
plastic transformation. It is of note, that our results, refer-
ring for the first time to paraffin-embedded cases, are in
line with the those previously reported on frozen materi-
al.10 Interestingly, our data seem to be in keeping with the
clinical results obtained by Enblad et al.,8 who found an
overall response rate of 36% in PTCL treated with alem-
tuzumab. 
Based on the above mentioned findings, the estimation
of CD52 expression may provide a rationale for the selec-
tion of patients with a higher probability of responding to
alemtuzumab by avoiding the risk of unwanted toxicity.
Certainly, this implies standardization of the techniques
adopted for CD52 evaluation. In our opinion, immuno-
histochemistry seems to represent an optimal approach.
It can be applied to routine material in phase of other pro-
teomic techniques, such as flow citometry or western
blot. In fact, such techniques require fresh material that is
only available in a small minority of lymphoma patients.
This deserves further evaluation within prospective clini-
cal trials.
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Addendum: after the acceptance of the present manuscript, similar
immunohistochemical findings were reported by Rodig et al., cited in
ref. #11. 
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